Table 2 Time-to-event outcomes in VeriStrat- and treatment-defined groups of patients

From: Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy

 

PFS

OS

Patient groups

Median (95% CI), month

HR (95% CI)

Log-rank P

Median (95% CI), month

HR (95% CI)

Log-rank P

VSG

6.5 (3.9–8.8)

0.36a (0.22–0.61)

<0.0001

10.8 (7.8–17.7)

0.26a (0.15–0.47)

<0.0001

VSP

1.6 (1.1–2.5)

  

3.4 (2.4–4.3)

  

VSG Carbo/Pem

3.8 (2.7–8.7)

0.30a (0.14–0.62)

0.0007

9.4 (5.0–15.3)

0.26a (0.12–0.55)

0.0002

VSP Carbo/Pem

1.6 (1.0–2.5)

  

3.4 (1.0–4.3)

  

VSG Cis/Pem

7.9 (5.2–13.1)

0.39a (0.18–0.85)

0.0141

17.7 (9.9–24.9)

0.25a (0.10–0.62)

0.0013

VSP Cis/Pem

1.7 (1.1–3.9)

  

4.2 (2.6–8.9)

  

Carbo/Pem

2.8 (2.0–4.0)

1.59b (0.97–2.61)

0.0627

6.0 (4.2–10.0)

1.64b (0.96–2.82)

0.0701

Cis/Pem

5.7 (3.8–8.8)

  

10.3 (6.6–17.9)

  
  1. Abbreviations: CI=confidence interval; Carbo=carboplatin; Cis=cisplatin; HR=hazard ratio; N/R=not reached; OS=overall survival; Pem=pemetrexed; PFS=progression-free survival; VSG=VeriStrat Good; VSP=VeriStrat Poor.
  2. aHR calculated for VeriStrat Good vs VeriStrat Poor using unadjusted Cox proportional hazard model.
  3. bHR calculated for Carbo/Pem vs Cis/Pem using unadjusted Cox proportional hazard model.
Back to article page